2,620 Shares in argenx SE (NASDAQ:ARGX) Acquired by O Neil Global Advisors Inc.

O Neil Global Advisors Inc. acquired a new stake in argenx SE (NASDAQ:ARGX) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,620 shares of the company’s stock, valued at approximately $1,611,000. argenx makes up approximately 0.5% of O Neil Global Advisors Inc.’s portfolio, making the stock its 19th biggest position.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. FMR LLC grew its stake in argenx by 35.9% in the third quarter. FMR LLC now owns 4,793,472 shares of the company’s stock valued at $2,598,445,000 after purchasing an additional 1,265,486 shares during the last quarter. Lord Abbett & CO. LLC purchased a new position in argenx in the third quarter worth $88,339,000. Allspring Global Investments Holdings LLC grew its stake in argenx by 38,152.3% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company’s stock worth $89,391,000 after buying an additional 143,834 shares during the last quarter. Jennison Associates LLC increased its position in argenx by 27.0% during the 4th quarter. Jennison Associates LLC now owns 302,149 shares of the company’s stock valued at $185,821,000 after buying an additional 64,183 shares in the last quarter. Finally, Wellington Management Group LLP boosted its holdings in argenx by 13.0% in the third quarter. Wellington Management Group LLP now owns 482,346 shares of the company’s stock worth $261,470,000 after acquiring an additional 55,617 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on ARGX shares. Oppenheimer reissued an “outperform” rating and issued a $675.00 price objective (up from $646.00) on shares of argenx in a report on Thursday, November 21st. Guggenheim upped their price objective on shares of argenx from $585.00 to $665.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. Wedbush restated an “outperform” rating and issued a $655.00 price target on shares of argenx in a research note on Tuesday, December 3rd. Wolfe Research raised argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 target price for the company in a research note on Tuesday, November 12th. Finally, HC Wainwright reissued a “buy” rating and issued a $717.00 price target (up previously from $670.00) on shares of argenx in a report on Tuesday, January 14th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $658.39.

argenx Trading Up 1.1 %

argenx stock opened at $647.49 on Friday. argenx SE has a 12-month low of $349.86 and a 12-month high of $678.21. The stock has a market cap of $39.34 billion, a P/E ratio of -735.78 and a beta of 0.58. The company has a fifty day simple moving average of $642.31 and a 200-day simple moving average of $585.45.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.